Web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of ' Is insulin right for me? '.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/drug therapy ; Internet-Based Intervention*; Adult ; Australia ; Humans ; Insulin/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
    • Abstract:
      Introduction: Psychological barriers to insulin therapy are associated with the delay of clinically indicated treatment intensification for people with type 2 diabetes (T2D), yet few evidence-based interventions exist to address these barriers. We describe the protocol for a randomised controlled trial (RCT) examining the efficacy of a novel, theoretically grounded, psychoeducational, web-based resource designed to reduce psychological barriers to insulin among adults with non-insulin treated T2D: ' Is insulin right for me?' .
      Methods and Analysis: Double-blind, parallel group RCT. A target sample of N=392 participants (n=196/arm) will be randomised (1:1) to ' Is insulin right for me?' (intervention) or widely available online resources (control). Eligible participants include adults (18-75 years), residing in Australia, currently taking oral hypoglycaemic agents to manage T2D. They will be primarily recruited via invitations and reminders from the national diabetes registry (from a purposefully selected sample of N≥12 000).
      Exclusion Criteria: experience of self-administered injectable; previously enrolled in pilot RCT; 'very willing' to start insulin as baseline. Outcomes will be assessed via online survey at 2 weeks and 6 months. Primary outcome between-group: difference in mean negative Insulin Treatment Appraisal Scores (ITAS negative) at 2-week and 6-month follow-up.
      Secondary Outcomes: between-group differences in mean positive insulin appraisals (ITAS positive) and percentage difference in intention to commence insulin at follow-up time points. All data analyses will be conducted according to the intention-to-treat principle.
      Ethics and Dissemination: Deakin University Human Research Ethics Committee (2020-073). Dissemination via peer-reviewed journals, conferences and a plain-language summary.
      Trial Registration Number: ACTRN12621000191897; Australian and New Zealand Clinical Trials Registry.
      Competing Interests: Competing interests: EH-T has undertaken research funded by an unrestricted educational grant from Abbott Diabetes Care, AstraZeneca, and Sanofi; received speaker fees from Novo Nordisk and Roche to Australian Centre for Behavioural Research in Diabetes (ACBRD); and served on an advisory board for AstraZeneca. EEH has no conflicts of interest to disclose. JF has received unrestricted educational grants for research support from Roche, Sanofi, and Medtronic. TS serves on advisory boards for Novo Nordisk and Liva Health Care and is currently on a EIT Health research grant held jointly with Roche Diagnostics. JS has served on advisory boards for Janssen, Medtronic, Roche Diabetes Care, and Sanofi Diabetes; her research group (Australian Centre for Behavioural Research in Diabetes [(ACBRD])) has received honoraria for this advisory board participation and has also received unrestricted educational grants and in-kind support from Abbott Diabetes Care, AstraZeneca, Medtronic, Roche Diabetes Care, and Sanofi Diabetes. JS has also received sponsorship to attend educational meetings from Medtronic, Roche Diabetes Care, and Sanofi Diabetes, and consultancy income or speaker fees from Abbott Diabetes Care, AstraZeneca, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi Diabetes. All other authors have no conflicts of interest to declare.
      (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
    • References:
      Diabet Med. 2020 Sep;37(9):1427-1442. (PMID: 31968127)
      Diabetes Care. 2013 Nov;36(11):3411-7. (PMID: 23877982)
      Diabet Med. 2013 May;30(5):512-24. (PMID: 23323988)
      Ther Adv Endocrinol Metab. 2019 May 03;10:2042018819844694. (PMID: 31105931)
      Diabetes Res Clin Pract. 2016 Apr;114:126-35. (PMID: 26818893)
      Diabetes Res Clin Pract. 2017 Nov;133:204-210. (PMID: 29122108)
      Diabetes Care. 2015 Jan;38(1):140-9. (PMID: 25538310)
      Health Qual Life Outcomes. 2014 Jun 06;12:87. (PMID: 24902877)
      Cardiovasc Diabetol. 2015 Aug 07;14:100. (PMID: 26249018)
      Health Psychol. 2008 May;27(3):379-87. (PMID: 18624603)
      Diabet Med. 2015 Mar;32(3):407-13. (PMID: 25251768)
      BMJ Open. 2021 Sep 24;11(9):e045853. (PMID: 34561252)
      Patient Educ Couns. 2015 Sep;98(9):1123-30. (PMID: 26054453)
      Diabetes Care. 1995 Jun;18(6):754-60. (PMID: 7555499)
      Diabetes Ther. 2018 Feb;9(1):113-124. (PMID: 29218568)
      J Clin Nurs. 2017 Jun;26(11-12):1705-1713. (PMID: 27602873)
      Patient. 2014;7(4):437-50. (PMID: 24958464)
      Diabetes Care. 2018 Dec;41(12):2669-2701. (PMID: 30291106)
      Can J Diabetes. 2021 Apr;45(3):273-281.e13. (PMID: 33160883)
      Prim Care Diabetes. 2017 Oct;11(5):474-481. (PMID: 28705697)
      Ann Behav Med. 2013 Aug;46(1):81-95. (PMID: 23512568)
      Curr Med Res Opin. 2016;32(4):681-6. (PMID: 26743676)
      Med J Aust. 2014 Dec 11;201(11):650-3. (PMID: 25495309)
      Health Qual Life Outcomes. 2007 Dec 20;5:69. (PMID: 18096074)
      BMC Public Health. 2012 Feb 12;12:120. (PMID: 22325032)
      J Psychosom Res. 2006 Jun;60(6):631-7. (PMID: 16731240)
      Aust Fam Physician. 2011 Aug;40(8):617-21. (PMID: 21814661)
      J Med Internet Res. 2013 Dec 13;15(12):e279. (PMID: 24334230)
      Diabet Med. 2015 Oct;32(10):1297-303. (PMID: 25683652)
      Diabet Med. 2017 Jan;34(1):14-26. (PMID: 26996982)
      Diabetes Educ. 2016 Apr;42(2):178-87. (PMID: 26769757)
      Clin Diabetes. 2020 Oct;38(4):371-381. (PMID: 33132507)
      Diabetes Ther. 2020 Jan;11(1):119-132. (PMID: 31732858)
      BMJ. 2017 Mar 8;356:j783. (PMID: 28274941)
      Curr Med Res Opin. 2011 Jun;27(6):1169-74. (PMID: 21469914)
      J Diabetes Complications. 2019 Apr;33(4):307-314. (PMID: 30709604)
      Implement Sci. 2012 Apr 24;7:37. (PMID: 22530986)
      Diabet Med. 2022 Mar;39(3):e14759. (PMID: 34865232)
      J Diabetes Complications. 2016 Aug;30(6):1151-7. (PMID: 27114388)
      N Engl J Med. 2008 Oct 9;359(15):1577-89. (PMID: 18784090)
      Aust J Prim Health. 2015;21(3):327-33. (PMID: 25007788)
    • Contributed Indexing:
      Keywords: clinical trials*; diabetes & endocrinology*; social medicine*
    • Accession Number:
      0 (Insulin)
    • Publication Date:
      Date Created: 20220222 Date Completed: 20220322 Latest Revision: 20220531
    • Publication Date:
      20231215
    • Accession Number:
      PMC8862461
    • Accession Number:
      10.1136/bmjopen-2021-051524
    • Accession Number:
      35190420